Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens

Trial Profile

Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Dendritic cell vaccines-Medigene Immnotherapies (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MediGene AG
  • Most Recent Events

    • 22 Mar 2018 According to a Medigene media release, the company will present preliminary data on certain aspects of the trial at scientific conferences in 2018.
    • 16 Mar 2018 According to a Medigene media release, company will present a poster at American Association for Cancer Research (AACR) Annual Meeting .
    • 18 Dec 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top